SF3B1: from core splicing factor to oncogenic driver

Area of Science:

• Molecular Biology
• Cancer Genetics
• RNA Splicing

Background:

• Somatic mutations in SF3B1, a core splicing factor, are prevalent drivers across various cancer types.
• SF3B1 functions as a scaffold protein, crucial for spliceosome assembly and accurate pre-mRNA splicing, particularly branchsite recognition.

Purpose of the Study:

• To elucidate the molecular mechanisms by which oncogenic SF3B1 mutations disrupt splicing.
• To discuss the role of SF3B1-mutant-specific aberrant splicing in cancer initiation and progression.
• To highlight the prognostic significance of SF3B1 mutations for targeted therapy development.

Main Methods:

• Review of molecular mechanisms underlying SF3B1-mediated splicing disruption.
• Analysis of transcriptomic alterations in SF3B1-mutant cancer cells.
• Correlation of SF3B1 mutation status with cancer phenotypes and prognosis.

Main Results:

• SF3B1 mutations perturb early spliceosomal complexes, leading to alternative branchpoint activation and cryptic 3' splice site selection.
• Aberrantly spliced transcripts in SF3B1-mutant cancers contribute to tumorigenesis.
• Distinct SF3B1 mutations correlate with specific disease phenotypes and prognostic outcomes.

Conclusions:

• Understanding SF3B1's role in splicing disruption is key to comprehending its oncogenic potential.
• Targeting SF3B1-mutant-specific splicing defects presents a promising therapeutic strategy.
• Further research into SF3B1 mutation-driven cancer biology is critical for clinical advancements.